Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: Ancillary results of the KYOTO HEART study

Clinical and Experimental Hypertension

Volumn 34, Issue 2, 2012, Pages 153-159

  Sawada, Takahisa ^a   Yamada, Hiroyuki ^a   Shiraishi, Jun ^b   Kimura, Shinzo ^c   Matsubara, Hiroaki ^a  

^a KYOTO PREFECTURAL UNIVERSITY   (Japan)

^b KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Angiotensin receptor blockers; Calcium channel blockers; Combination therapy; High risk hypertension; Valsartan

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; AZELNIDIPINE; BENIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; DILTIAZEM; DIURETIC AGENT; EFONIDIPINE; MANIDIPINE; MEPIRODIPINE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; THIAZIDE DIURETIC AGENT; VALSARTAN;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; AGED; ALPHA ADRENERGIC RECEPTOR BLOCKING; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; AORTA DISSECTING ANEURYSM; ARTERY OCCLUSION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART FAILURE; HEART RATE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE;

AGED; ANGINA PECTORIS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; STROKE; TETRAZOLES; VALINE;

EID: 84859615265     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2011.577493     Document Type: Article

References (19)

1. Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C. World Heart Day 2002: The international burden of cardiovascular disease: Responding to the emerging global epidemic. Circulation 2002; 106:1602-1605.
2. Rodgers A, Ezzati M, Vander Hoorn S, Lopez AD, Lin RB, Murray CJ. Distribution of major health risks: Findings from the Global Burden of Disease study. PLoS Med 2004; 1:e27.
3. Fleck F. Cardiovascular disease - a global health time bomb. Bull World Health Organ 2004; 82:470-471.
4. Hollenberg NK. European Society of Cardiology: Angiotensin II antagonists in hypertension and beyond. Angiotensin II antagonists: Why is there so much excitement? Am J Manag Care 1998; 4(Suppl. 7):S384-S387.
5. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: Clinical evidence of improved patient outcomes: Part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation 2006; 114:2871-2891. (Pubitemid 46018289)
6. Sawada T, Takahashi T, Yamada H, Dahlöf B, Matsubara H, KYOTO HEART Study Group. Rationale and design of the KYOTO HEART study: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events. J Hum Hypertens 2009; 23:188-195.
7. Sawada T, Yamada H, Dahlöf B, Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009; 30:2461-2469.
8. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289:2560-2572. (Pubitemid 37430158)
9. Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462-1536.
10. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) (published correction appears in Hypertens Res 2009; 32:318). Hypertens Res 2009; 32:3-107.
11. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
12. Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439. (Pubitemid 46635780)
13. Kubota N, Miyauchi K, Kasai T, et al. Synergistic effects of calcium-channel and angiotensin-receptor blockers on endothelial function and inflammatory responses in a porcine drugeluting stent model. Circ J 2010; 74:1536-1537.
14. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blind endpoint (PROBE) study. A novel design for intervention trials. Blood Press 1992; 1:113-119.
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
16. Chobanian AV. Does it matter how hypertension is controlled? N Engl J Med 2008; 359:2485-2488.
17. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15:327-331. (Pubitemid 20097461)
18. Luscher TF, Wenzel RR, Moreau P, Takase H. Vascular protective effects of ACE inhibitors and calcium antagonists: Theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardiovasc Drugs Ther 1995; 9(Suppl. 3):509-523.
19. Staessen JA, Richart T. Sum and substance in the Jikei Heart Study. Lancet 2007; 369:1407-1408. (Pubitemid 46635762)